Cargando…

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction

BACKGROUND: Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease (FD). METHODS AND RESULTS: Plasma biomarkers were studied in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yogasundaram, Haran, Nikhanj, Anish, Putko, Brendan N., Boutin, Michel, Jain‐Ghai, Shailly, Khan, Aneal, Auray‐Blais, Christiane, West, Michael L., Oudit, Gavin Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404196/ https://www.ncbi.nlm.nih.gov/pubmed/30571380 http://dx.doi.org/10.1161/JAHA.118.009098

Ejemplares similares

Clinical utility of 12‐lead electrocardiogram in evaluating heart disease in patients with muscular dystrophy: Assessment of left ventricular hypertrophy, conduction disease, and cardiomyopathy
por: Nikhanj, Anish, et al.
Publicado: (2021)

Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology
por: Putko, Brendan N., et al.
Publicado: (2014)

Cardiac Intervention Improves Heart Disease and Clinical Outcomes in Patients With Muscular Dystrophy in a Multidisciplinary Care Setting
por: Nikhanj, Anish, et al.
Publicado: (2020)

Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic
por: Gagnon, Luke R., et al.
Publicado: (2022)

Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction
por: Alyamani, Motasem, et al.
Publicado: (2018)

Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
por: Mhanni, Aizeddin A., et al.
Publicado: (2020)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure
por: Yogasundaram, Haran, et al.
Publicado: (2018)

Lentivirus-mediated gene therapy for Fabry disease
por: Khan, Aneal, et al.
Publicado: (2021)

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
por: Saleh, Amr H., et al.
Publicado: (2023)

Reduced native right ventricular T(1 )in Anderson-Fabry disease as compared to patients with pulmonary hypertension
por: Pagano, Joseph J, et al.
Publicado: (2014)

Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
por: Boutin, Michel, et al.
Publicado: (2020)

Reduced Right Ventricular Native Myocardial T(1) in Anderson-Fabry Disease: Comparison to Pulmonary Hypertension and Healthy Controls
por: Pagano, Joseph J., et al.
Publicado: (2016)

Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion
por: Kamani, Mustafa A, et al.
Publicado: (2016)

Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry
por: Auray-Blais, Christiane, et al.
Publicado: (2021)

Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series
por: Nikhanj, Anish, et al.
Publicado: (2019)

Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations
por: Nikhanj, Anish, et al.
Publicado: (2022)

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34(+) Cells for Correction of Fabry Disease
por: Huang, Ju, et al.
Publicado: (2017)

Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS
por: Menkovic, Iskren, et al.
Publicado: (2019)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation
por: Valtola, Kati, et al.
Publicado: (2023)

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort
por: Ezekowitz, Justin A., et al.
Publicado: (2017)

Cardiac manifestations and clinical management of X-linked Emery-Dreifuss muscular dystrophy: a case series
por: Kashyap, Niharika, et al.
Publicado: (2023)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure
por: Patel, Vaibhav B., et al.
Publicado: (2012)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction
por: Howlett, Jonathan G., et al.
Publicado: (2020)

A biobank management model applicable to biomedical research
por: Auray-Blais, Christiane, et al.
Publicado: (2006)

Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach
por: Menkovic, Iskren, et al.
Publicado: (2020)

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2016)

Animal models of heart failure with preserved ejection fraction
por: Conceição, G., et al.
Publicado: (2016)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
por: Nanayakkara, Shane, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rg650bhaudii8plha8ebbg517h